Comparative Pharmacology
Head-to-head clinical analysis: INDIUM IN 111 PENTETREOTIDE KIT versus XENOVIEW.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDIUM IN 111 PENTETREOTIDE KIT versus XENOVIEW.
INDIUM IN-111 PENTETREOTIDE KIT vs XENOVIEW
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indium In-111 pentetreotide binds to somatostatin receptors, particularly subtypes 2 and 5, allowing scintigraphic localization of primary and metastatic neuroendocrine tumors bearing these receptors.
Xenoview is a paramagnetic contrast agent for MRI that enhances T1 relaxation by shortening the longitudinal relaxation time of water protons in tissues where it accumulates, thereby increasing signal intensity on T1-weighted images.
111 MBq (3 mCi) indium In-111 pentetreotide administered intravenously over 1 minute; single dose for planar and SPECT imaging.
Not applicable (diagnostic agent, not therapeutic); refer to imaging protocol.
None Documented
None Documented
Terminal half-life approximately 24 hours (range 22-26 hours), allowing imaging up to 24-48 hours post-injection
Terminal elimination half-life is 3-5 hours in patients with normal renal function; may be prolonged in renal impairment.
Renal: 80-90% unchanged within 24 hours; Fecal: 5-10%
Primarily renal excretion (60-70% unchanged drug), with 20-25% biliary/fecal elimination.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical